Louise Barrett | SVP, Legal Affairs |
Corey Fishman | CEO |
Judy Matthews | CFO |
Gregory Renza | RBC Capital Markets |
Ed Arce | H.C. Wainwright |
Kevin Kedra | Gabelli Research |
Good morning everyone and welcome to Iterum Therapeutics Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Conference Call.
Our press release with the Company’s fourth quarter and full year 2020 results was issued earlier this morning, and can be found on our website.
We’re joined this morning by Corey Fishman, our CEO; and Judy Matthews CFO. Corey will provide opening remarks, Judy will provide details on our financial results, and then we’ll open the lines for Q&A.
Before we begin, I’d like to remind you that this call will contain forward-looking statements concerning our plans, strategies and prospects for our business including with respect to the timing of review by the FDA of our NDA for oral sulopenem, our expectations for potential approval on the PDUFA date, the market potential for sulopenem, commercialization activities including the ability to enter into a definitive agreement with respect to commercialization services, the ability to expand any approved label for oral sulopenem, including adding additional indication, and the sufficiency of our cash resources to execute our strategy.